CA2441535A1 - Methods for delivering nucleic acid molecules into cells and assessment thereof - Google Patents

Methods for delivering nucleic acid molecules into cells and assessment thereof Download PDF

Info

Publication number
CA2441535A1
CA2441535A1 CA002441535A CA2441535A CA2441535A1 CA 2441535 A1 CA2441535 A1 CA 2441535A1 CA 002441535 A CA002441535 A CA 002441535A CA 2441535 A CA2441535 A CA 2441535A CA 2441535 A1 CA2441535 A1 CA 2441535A1
Authority
CA
Canada
Prior art keywords
cells
methods
nucleic acid
acid molecules
assessment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002441535A
Other languages
French (fr)
Other versions
CA2441535C (en
Inventor
Volker Oberle
Dirk Hoekstra
Jan Drayer
Paul Peter Tak
Gary Dejong
Sandra Louise Vanderbyl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Chromos Molecular Systems, Inc.
Volker Oberle
Dirk Hoekstra
Jan Drayer
Paul Peter Tak
Gary Dejong
Sandra Louise Vanderbyl
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,981 external-priority patent/US6936469B2/en
Priority claimed from US09/815,979 external-priority patent/US7294511B2/en
Priority claimed from US10/086,745 external-priority patent/US20030186390A1/en
Application filed by Chromos Molecular Systems, Inc., Volker Oberle, Dirk Hoekstra, Jan Drayer, Paul Peter Tak, Gary Dejong, Sandra Louise Vanderbyl, Glaxo Group Limited filed Critical Chromos Molecular Systems, Inc.
Priority to CA002633522A priority Critical patent/CA2633522A1/en
Publication of CA2441535A1 publication Critical patent/CA2441535A1/en
Application granted granted Critical
Publication of CA2441535C publication Critical patent/CA2441535C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Methods for delivering nucleic acid molecules into cells and methods for measuring nucleic acid delivery into cells and the expression of the nucleic acids are provided. The methods are designed for introduction of large nucleic acid molecules, including artificial chromosomes, into cells, and are practiced in vitro and in vivo.
CA002441535A 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof Expired - Fee Related CA2441535C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002633522A CA2633522A1 (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/815,979 2001-03-22
US09/815,981 US6936469B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US09/815,979 US7294511B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US09/815,981 2001-03-22
US10/086,745 US20030186390A1 (en) 2001-03-22 2002-02-28 Methods for delivering nucleic acid molecules into cells and assessment thereof
US10/086,745 2002-02-28
PCT/US2002/009262 WO2002076508A1 (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002633522A Division CA2633522A1 (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Publications (2)

Publication Number Publication Date
CA2441535A1 true CA2441535A1 (en) 2002-10-03
CA2441535C CA2441535C (en) 2008-08-26

Family

ID=27375461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002441535A Expired - Fee Related CA2441535C (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Country Status (6)

Country Link
EP (1) EP1383541A4 (en)
JP (1) JP2004532205A (en)
CA (1) CA2441535C (en)
IL (1) IL157703A0 (en)
NZ (1) NZ527972A (en)
WO (1) WO2002076508A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294511B2 (en) 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
NZ545697A (en) 2001-05-30 2008-06-30 Glaxo Group Ltd A lambda-intR mutein comprising a glutamic acid to arginine change at position 174 of Wt lambda-intR
JP4676679B2 (en) * 2003-04-02 2011-04-27 帝人株式会社 Artificial cartilage
EP2527456B1 (en) 2004-10-22 2018-05-16 Revivicor Inc. Transgenic porcines lacking endogenous immunoglobulin light chain
JP5115686B2 (en) * 2006-04-17 2013-01-09 学校法人慶應義塾 Drug introduction device to cells
ES2548377T3 (en) 2008-10-27 2015-10-16 Revivicor, Inc. Immunosuppressed ungulates
CN109963506A (en) * 2016-11-22 2019-07-02 西达-赛奈医疗中心 A kind of novel transfection and drug delivery device
CN117357480B (en) * 2023-12-08 2024-03-29 北京中科利华医药研究院有限公司 Composition for needleless percutaneous injection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135313A1 (en) * 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
NL1000884C2 (en) * 1995-07-25 1997-01-28 Univ Groningen Transport vehicles for macromolecules.
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
WO1999025385A1 (en) * 1997-11-17 1999-05-27 Imarx Pharmaceutical Corp. A method of increasing nucleic acid synthesis with ultrasound
WO2000034436A2 (en) * 1998-12-04 2000-06-15 Genetronics, Inc. Facs assisted methods for introducing individual chromosomes into cells

Also Published As

Publication number Publication date
IL157703A0 (en) 2004-03-28
EP1383541A4 (en) 2009-11-04
EP1383541A1 (en) 2004-01-28
WO2002076508B1 (en) 2002-12-12
JP2004532205A (en) 2004-10-21
CA2441535C (en) 2008-08-26
NZ527972A (en) 2006-04-28
WO2002076508A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
ATE237312T1 (en) NUCLEIC ACID COMPLEXES ENCAPSULATED IN LIPOSOMES
WO2003093449A3 (en) Methods for delivery of nucleic acids
BR9910251A (en) Hematopoietic stimulation
AU2821297A (en) In vivo gene transfer methods for wound healing
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
AU2001294890A1 (en) Pei: dna vector formulations for in vitro and in vivo gene delivery
HUP0004728A1 (en) Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
HK1020756A1 (en) Use of angiogenic factor vegf145 in treating cardiovascular disease
WO1991009958A3 (en) Method of delivering molecules into eukaryotic cells
ATE279912T1 (en) METHOD FOR CELL TRANSFECTION WITH LIPOSOMAL-ENCAPSULED NUCLEIC ACIDS
EP2298355A3 (en) Albumin fusion proteins
DE60023600D1 (en) Replicating retroviral constructs, their production and uses for gene transfer
EP2213302A3 (en) DR4 antibodies and uses thereof
HUP0001937A2 (en) Compounds, preparation and use for transferring nucleic acids into cells
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
EP3467112A3 (en) Methods for transfecting nucleic acids into live cells
IL134593A0 (en) A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2000067697A3 (en) Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
GB2350060A (en) Nucleic acid delivery
WO2003099228A3 (en) Compositions and processes for inhibiting gene expression using polynucleotides
CA2375549A1 (en) Delivery system for biological material
WO1999059638A8 (en) Compositions and methods for the delivery of nucleic acid molecules
WO2002036167A8 (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150323